Alto Neuroscience Announces $50 Million Private Placement Financing
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Business Wire
– Financing led by Perceptive Advisors with participation from new and existing biotech focused investors –– Alto expects to use the proceeds of this financing to accelerate development of ALTO-207 in Treatment Resistant Depression – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $50 million, before deducting offering expenses. The financing was led by Perceptive Advisors, with participation by new and existing institutional investors, including Commodore Capital, Vestal Point Capital, Vivo Capital, and a large biotech dedicated investor.Alto intends to use the proceeds from the PIPE to accelerate th
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08Business Wire
- Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)GlobeNewswire
- Alto Neuroscience (NYSE:ANRO) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.MarketBeat
- Alto Neuroscience (NYSE:ANRO) is now covered by analysts at BTIG Research. They set a "buy" rating and a $27.00 price target on the stock.MarketBeat
- Alto Neuroscience (NYSE:ANRO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ANRO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
ANRO
Earnings
- 11/12/25 - Beat
ANRO
Sec Filings
- 11/28/25 - Form S-3
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- ANRO's page on the SEC website